10-Q: Exagen Inc. Reports Q1 2024 Results: Revenue Up, Losses Narrowed

Exagen Inc. saw a 28.4% increase in revenue and a significant reduction in net loss for the first quarter of 2024 compared to the same period last year.

Summary

• Exagen Inc. reported a net loss of $3.36 million for the first quarter of 2024, a significant improvement from the $7.69 million loss in the same period of 2023.
• Revenue for the quarter increased by 28.4% to $14.4 million, up from $11.2 million in Q1 2023, driven by improved average selling prices and cash collections.
• The company delivered 30,263 AVISE CTD tests in Q1 2024, a 19% decrease compared to the 37,312 tests delivered in Q1 2023.
• Gross margin improved to 59.6% in Q1 2024 from 47.2% in Q1 2023, due to changes in revenue and cost of revenue.
• Operating expenses decreased by 8% year-over-year, primarily due to reduced selling, general, and administrative costs.
• The company's cash and cash equivalents stood at $27.3 million as of March 31, 2024, with an accumulated deficit of $282.6 million.
• Exagen anticipates that its current capital resources will be sufficient to fund its obligations for at least the next twelve months.

Sentiment

Score: 7

Explanation: The document shows a positive trend with increased revenue and reduced losses, but there are still significant risks and challenges, including regulatory uncertainty and the need for additional funding. The company is making progress, but it is not without its hurdles.

Positives

• The company experienced a significant increase in revenue, driven by improved average selling prices and cash collections.
• Net losses were substantially reduced compared to the same quarter last year.
• Gross margin improved significantly, indicating better cost management and pricing strategies.
• Operating expenses decreased, reflecting cost-cutting measures and improved efficiency.
• The company is actively developing and incorporating new biomarkers into its tests, which could enhance diagnostic capabilities and market position.
• Exagen has secured a Proprietary Laboratory Code (PLA) for its AVISE Lupus test, which is priced at $840.65 per test through December 31, 2025.

Negatives

• The number of AVISE CTD tests delivered decreased by 19% year-over-year.
• The company continues to operate at a loss, with an accumulated deficit of $282.6 million.
• Exagen is dependent on a limited number of payors, with Medicare and Medicare Advantage accounting for a significant portion of revenue and accounts receivable.
• The company relies on two suppliers for a majority of its diagnostic testing supplies, posing a supply chain risk.
• The company is experiencing denials from commercial payors due to unfavorable medical policies.
• The company is holding claims in the first half of the year which will likely result in increases in accounts receivable and an accelerated decrease in cash.

Risks

• The company's revenue is dependent on achieving broad coverage and reimbursement for its tests from third-party payors.
• Changes in estimated reimbursements for tests performed in prior periods can impact revenue in the current period.
• The company is subject to potential regulatory changes, including the FDA's proposed rule to regulate laboratory developed tests (LDTs).
• The company may need additional funding to support its operations and growth strategy.
• Failure to achieve performance covenants under the Amended Loan Agreement could trigger the need for a new financial plan and additional capital raising.
• The company is subject to legal proceedings and claims that could have an adverse impact on its business.

Future Outlook

The company expects to continue to incur operating losses in the near term, but anticipates that its current capital resources will be sufficient to fund its obligations for at least the next twelve months. They plan to incorporate new biomarkers into their tests by the end of 2024, which they believe will further differentiate their core test offerings and be accretive to their financial performance.

Management Comments

• Management believes that its existing capital resources will be sufficient to fund the Company's obligations for at least twelve months following the issuance of these condensed financial statements.
• Management expects that selling, general and administrative expenses will increase year-over-year in the near-term as a result of expected additions to headcount and associated increases for personnel costs.
• Management expects that research and development expenses will remain relatively consistent year-over-year in the near-term.

Industry Context

The company operates in the diagnostics industry, specifically focusing on autoimmune diseases. The development and commercialization of innovative testing products like AVISE CTD and AVISE Lupus are aimed at addressing the unmet needs of rheumatologists. The company's focus on specialized sales personnel and customer service positions them well in this market. The regulatory landscape for laboratory developed tests (LDTs) is evolving, which could impact the company's operations and require additional clinical trials or regulatory approvals.

Comparison to Industry Standards

• Exagen's revenue growth of 28.4% year-over-year is a positive sign, but the 19% decrease in test volume indicates potential challenges in market penetration.
• The improvement in gross margin to 59.6% suggests better cost management compared to previous periods, but it is important to compare this to industry benchmarks for diagnostic companies.
• Companies like Myriad Genetics and Exact Sciences, which also focus on molecular diagnostics, have reported varying gross margins and revenue growth rates, making a direct comparison challenging without specific data.
• The regulatory uncertainty surrounding LDTs is a common challenge for companies in this space, and Exagen's response to the FDA's proposed rule will be critical.
• Exagen's reliance on a limited number of payors is a risk that is also faced by other diagnostic companies, but diversification of payors is a key strategy for long-term sustainability.
• The company's focus on incorporating new biomarkers into its tests is a positive step, as innovation is crucial for maintaining a competitive edge in the diagnostics market.

Legal Proceedings

• The company resolved an investigation with the U.S. Attorneys Office for the District of Massachusetts in October 2023, making a $0.7 million payment.
• The company is currently involved in a qui tam lawsuit, and has filed a motion to dismiss the complaint.

Stakeholder Impact

• Shareholders may see increased value due to improved financial performance, but are also exposed to risks related to regulatory changes and the need for additional funding.
• Employees may benefit from the company's growth, but may also be affected by cost-cutting measures.
• Customers (rheumatologists and patients) may benefit from enhanced diagnostic capabilities with the incorporation of new biomarkers.
• Suppliers may be impacted by the company's financial performance and any changes in supply agreements.
• Creditors are exposed to risks related to the company's debt obligations and financial performance.

Next Steps

• The company plans to incorporate three new biomarkers into its AVISE Lupus test toward the end of 2024.
• The company plans to incorporate new biomarkers specific to seronegative rheumatoid arthritis into its AVISE CTD test toward the end of 2024.
• The company will continue to monitor and respond to the FDA's proposed rule on LDTs.
• The company will continue to implement revenue cycle management initiatives to optimize cash collections.

Key Dates

Keywords

AVISE CTD, Autoimmune Disease, Rheumatology, Diagnostics, Laboratory Developed Tests, Medicare, Revenue, Net Loss, Biomarkers, Reimbursement